Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2021-04-28 Capital/Financing Update
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Regeneus partners with Defence to treat combat casualties 2 pages 141.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 29 April 2021 about Regeneus partnering with the Australian Department of Defence to develop a product called Sygenus. It discusses funding details, the nature of the technology, and the research partnership. There are no financial statements, quarterly or annual results, or detailed financial data. The document is a corporate announcement about a partnership and funding for research, not a financial report or regulatory filing. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under Capital/Financing Update (CAP) as it announces funding and partnership related to development and research activities.
2021-04-28 English
Regeneus to be granted key Progenza patent in Europe 1
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 16 March 2021 regarding the European Patent Office's Notice of Intention to grant a new patent for Regeneus' stem cell technology platform Progenza™. The content focuses on intellectual property and commercial rights, with no financial data, regulatory certifications, or detailed financial reports. The document is relatively short (2521 characters) and serves as a news announcement about a patent grant intention rather than a financial or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings related to financial or governance matters. The best fitting category is a general Regulatory Filing (RNS) as it is a regulatory announcement about intellectual property status relevant to investors but not a financial report or management change.
2021-03-15 English
Regeneus Company Update Investor Webcast Presentation 26 pages 1.2MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement dated 3 March 2021 from Regeneus Ltd, describing an investor webcast presentation and providing a detailed investor presentation about the company's technology, products, management team, and financial overview. The text includes disclaimers typical of investor presentations and forward-looking statements. There is no indication that this is a full annual or interim report, audit report, earnings release, or regulatory filing. The document is a detailed presentation aimed at investors, focusing on company strategy, technology, and market position. Therefore, it fits the definition of an Investor Presentation (IP). The document length (15,000 characters) supports that it is a full presentation rather than a brief announcement or summary.
2021-03-02 English
Appendix 3Z Final Director's Interest Notice Dr Alan Dunton 2 pages 218.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the cessation of a director and the director's relevant interests in securities, including unlisted options that lapsed. This is a formal notification of a director's personal share transactions and interests, consistent with insider trading disclosures. The document is short (2230 characters) and focused solely on director share interests and cessation, with no financial statements or broader company performance data. Therefore, it fits the category of Director's Dealing (DIRS).
2021-02-28 English
Appendix 4D and Half-Year Report 22 pages 1.2MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'ASX Half-Year Report for 6 months to 31 December 2020' and contains detailed financial results, directors' report, auditor's review, consolidated financial statements, and notes. It covers a half-year period and includes substantive financial data and analysis, such as revenues, profit, cash flows, expenses, and operational review. The presence of an independent auditor's review report and directors' declaration further confirms it is a formal interim financial report. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content and structure align with the definition of an Interim / Quarterly Report (IR). H1 2021
2021-02-25 English
Half-Year Results and Business Update 4 pages 163.9KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 26 February 2021 titled 'Half-Year Results & Business Update' for the period ended 31 December 2020 (H1 FY2021). It contains financial highlights such as profit, revenue, cash balance, and milestone payments, as well as business updates including licensing agreements, patent grants, and CEO appointment. The document includes substantive financial data and analysis for a half-year period, which aligns with the definition of an Interim / Quarterly Report (IR). It is not merely an announcement of a report or a certification, but a comprehensive financial and business update for the half-year period. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2021
2021-02-25 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.